



## PROSTATE CANCER OUTCOMES

#### LIFE AFTER PROSTATE CANCER DIAGNOSIS

#### Decision regret in men treated with curative intent for prostate cancer: results from the Life After Prostate Cancer Diagnosis study

Amy Downing, **Penny Wright**, Eila Watson, Richard Wagland, Luke Hounsome, Hugh Butcher, Anna Gavin, Adam Glaser.

Poster Wagland et al: The quality of treatment decision-making amongst men with prostate cancer: preliminary qualitative findings from the Life After Prostate Cancer Diagnosis (LAPCD) study













# Incidence and survival



- Prostate cancer (PCa) is the commonest cancer in men in the United Kingdom (UK)
  - Stage 1: 30% of cases
  - Stage 2: 20% of cases

almost everyone will survive their cancer for 5 years +

• Stage 3: 19% of cases

almost 95% will survive their cancer for 5 years +

Cancer Research UK













## Treatment options



Treatment options for stage 1 & 2 prostate cancer

- Active surveillance (no treatment)
- Surgery
- Radiotherapy
- May go on to receive androgen-deprivation therapy ADT (hormones)

Treatment options for stage 3 (locally advanced) prostate cancer

- Try and cure the cancer often with multiple radical treatments
- Accept incurability and go to Watchful Waiting (no treatment)












## **Patient Reported Outcomes**




























# Treatment decision making

DOME -Our Specialist Werses 0600 074 6383 THE OWNER WATER 23808 PROTOCT INCOMMENTS ALL DRIVEN AUT IS LET INVITUTED **BESIDEN** FOR HEM TH PROFESSIONAL!! Treatments · Problet mitamation Channey a bastiment falles up after imainent I mar prezide career comer herit HEE NEW! You are here: Home > Prostate information > Treatments > Choosing a beatment **Choosing a treatment** ON THIS PAGE -What affects my treatment options? Your beatment options will depend on whether your cancer is contained within the prostate gland (localized), has spread and extends of the prostate dowally astronamilier had spread to other parts of the hody comment

#### Shared decision making is encouraged





LIFE AFTER

DIAGNOSIS

PROSTATE CANCER

PROSTATE

OUTCOMES

CANCER











# Study Design



- Identified: Cancer Registration
- 18-42 months post diagnosis
- Cohort 1:
  - survey twice (12 months)
  - subset interviewed
- Cohort 2: survey once (England)
- Patient Reported Outcome Measures (PROMs)
- Data linkage



Downing et al. 2016, BMJ Open;6(12).















- Cohort 1, Time 1, England only
- PROMs
  - The Decision Regret Scale Brehaut et al. 2003, Medical Decision Making.;23(4):281-92.
  - Item on decision participation

"Do you think your views were taken into account when the team of doctors and nurses caring for you were discussing which treatment you should have?"

- EPIC-26 Wei et al, 2000; Urology. 56(6):899-905.
  - Five subscales (urinary x 2, bowel, sexual, hormonal)

















# 30,465 men participated (60%) 23,001 men were stage 1-3

## 17,292 (75.2%) completed the Decision Regret Scale












## **Decision regret**
































Least regret

England

**Public Health** 

LIFE AFTER

DIAGNOSIS


PROSTATE CANCER

PROSTATE

OUTCOMES

CANCER

- surgery alone
- brachytherapy alone
- monitoring (no treatment)




LIFE AFTER PROSTATE CANCER PROSTATE CANCER **OUTCOMES** DIAGNOSIS

# **Decision regret & PROMs**










Moderate or big bowel problem






















- 73% of men reported their views were <u>definitely</u> taken into account
- Decision regret was experienced by >60 % of men
- We don't know if they would have regretted a different treatment choice
- Less regret is associated with
  - Reporting being involved in the decision making process
  - Brachytherapy, surgery alone and monitoring
- Regret is associated, to an extent, with the level of 'problem' experienced















- Need to undertake more complex analysis/modelling
  - Include sociodemographic variables (e.g. age)
  - Include clinical variables (e.g. co-morbidity)
- Need to separate stage 1 & 2 from stage 3 to check if results remain constant
- Include data from the devolved nations

We would like to provide men and clinical teams with knowledge of specific personal issues for the men to consider when making their treatment choice, based on the findings of this population based study















## All the men who took part The LAPCD User Advisory Group The LAPCD Clinical & Scientific Advisory Group Prostate Cancer UK and MOVEMBER









